For the treatment of adolescents with uncontrolled moderate-to-severe atopic
dermatitis

DUPIXENT was studied in 1 pivotal trial

Evaluated in 251
adolescent patients
(12‑17 years) in
AD‑1526¹

Clinical trials in adolescents included 1 monotherapy trial (AD-1526) and 1 open-label extension trial (AD-1434). In AD-1526, patients were initiated with 2 DUPIXENT (200 mg or 300 mg) doses or placebo (subcutaneous injection) at Week 0 followed by 1 DUPIXENT (200 mg or 300 mg) dose or placebo every 2 weeks, based on the adolescent’s weight.¹

Disease severity was defined by an IGA score ≥3 in the overall assessment of atopic dermatitis lesions on a severity scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and a minimum body surface area involvement of ≥10%.^1,a

^aThese baseline characteristics are not meant for comparison.

^bEmollient background regimen was required.³

^cStudied vs placebo.

^dWeekly averaged Peak Pruritus NRS score (10 indicates the most severe).

Primary endpoint in the adolescent clinical trial: Change from baseline in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and a ≥2-point improvement at Week 16.¹

Other endpoints included change from baseline in the proportion of subjects with EASI-75 at Week 16 (improvement of
≥75%) and itch reduction defined by ≥4-point improvement in the Peak Pruritus NRS at Week 16.¹

EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; SC, subcutaneous.

See Peak Pruritus NRS Results

See IGA Results

See EASI Results

See safety profile